Company: PRGO
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001585364-25-000156
Chunk: 96

Company: PERRIGO Co plc
Filing Date: 2025-11-05
Form: 10-Q
Item: Part II, Item 1
Chunk 96
---
 allocated to our reporting segments and are recorded in Operating income (loss) on the Condensed Consolidated Statements of Operations. Unallocated expenses were as follows (in millions):

Three Months EndedNine Months EndedSeptember 27, 2025September 28, 2024September 27, 2025September 28, 2024$59.5 $70.7 $175.0 $253.6 

The decrease of $11.2 million and $78.6 million in unallocated expenses during the three and nine months ended September 27, 2025, respectively, compared to the prior year periods were due primarily to a decrease in expenses for litigation, as well as lower selling and administrative costs due primarily to Project Energize. 

51

Perrigo Company plc - Item 2Unallocated, Interest, Other, and Taxes

Interest expense, net, Other (income) expense, net and Loss on extinguishment of debt

Three Months EndedNine Months Ended(in millions)September 27, 2025September 28, 2024September 27, 2025September 28, 2024Interest expense, net$40.6 $57.6 $119.2 $144.7 Other (income) expense, net$9.6 $(4.1)$11.9 $(0.5)Loss on extinguishment of debt$— $5.1 $— $5.2 

Interest expense, net

The $17.0 million and $25.5 million decrease in Interest expense, net during the three and nine months ended September 27, 2025, respectively, compared to the prior year periods was due primarily to the absence of interest expense associated with the de-designation of interest rate swap agreements in the prior year and a decrease in interest expense associated with a decrease in outstanding borrowings under our Senior Secured Credit Facilities.

Other (income) expense, net

The $13.7 million and $12.4 million decrease in Other (income) expense, net during the three and nine months ended September 27, 2025, respectively, compared to the prior year periods was due primarily to unfavorable changes in revaluation of foreign currency contracts associated with the planned divestiture of the Dermacosmetics Business, the absence of prior year gain recognized on the sale of the Rare Diseases Business, and the loss recognized on the sale of the Richard B